R. K. Ramanathan

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT

Howard S. Höchster, Axel Grothey, L. Hart et al. · Annals of Oncology · 2014 · 66 citations · Full text

Medicine, Oncology, Pharmacology +12

N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study

Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton et al. · Journal of Clinical Oncology · 2004 · 62 citations

Pharmacy, Oncology, Pharmacotherapy +14

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

Howard Safran, R. K. Ramanathan, Jazmin Schwartz et al. · European Journal of Cancer · 2001 · 60 citations

Medicine, Oncology, Pharmacology +12

Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies

R. K. Ramanathan, Mace L. Rothenberg, Aimery de Gramont et al. · Annals of Oncology · 2009 · 47 citations · Full text

Medicine, Neurology, Oncology +13

Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies

W. Zamboni, Sandra Strychor, Lauren Maruca et al. · Clinical Pharmacology & Therapeutics · 2009 · 43 citations

Pharmacy, Pharmacokinetics, Pharmacology +11